Welcome to our dedicated page for Atricure news (Ticker: ATRC), a resource for investors and traders seeking the latest updates and insights on Atricure stock.
AtriCure, Inc. (symbol: ATRC) is a leading provider of cutting-edge medical technologies aimed at treating atrial fibrillation (Afib) and related conditions. With over 33 million people affected by Afib globally, AtriCure stands at the forefront of developing innovative solutions to combat this prevalent health issue. Electrophysiologists and cardiothoracic surgeons around the world rely on AtriCure's products to reduce complications associated with Afib.
The company's flagship product, the Isolator® Synergy™ Ablation System, is notably the first and only device approved by the FDA for the treatment of persistent Afib. Additionally, the AtriClip Left Atrial Appendage Exclusion System holds the title of the most widely sold LAA management device globally, with over 100,000 units implanted to date.
AtriCure's diverse product line includes solutions for Cryoablation, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, among others. They also offer a range of minimally invasive ablation devices and access tools catering to the increasing demand for less invasive cardiac and thoracic surgeries. Their products are distributed to medical centers through a combination of a direct sales force and a network of distributors.
Geographically, the majority of AtriCure's revenue is generated from the United States. The company continues to expand its impact through ongoing projects, research, and partnerships aimed at improving patient outcomes and advancing the field of cardiac surgery.
For more detailed information about AtriCure's latest developments, visit their official website at AtriCure.com or follow them on Twitter @AtriCure.
AtriCure, Inc. (Nasdaq: ATRC) has received CE-Mark approval to sell the EnCompass® Clamp in European Union countries. This regulatory approval marks a significant expansion of AtriCure's product line internationally. The EnCompass Clamp, which received FDA 510(K) clearance and was launched in the United States in 2022, provides a simpler and faster approach to ablating the heart in open-chest procedures.
Key features of the EnCompass Clamp include:
- Ability to perform comprehensive epicardial ablation of the left atrium in minutes
- Parallel closure, uniform pressure, and custom power using Synergy radiofrequency (RF)
- Magnetic guide for easier placement and more efficient procedures
- Design that fits cardiac anatomy, supporting surgical ablation in procedures like CABG and AVR
AtriCure estimates approximately 400,000 cardiac surgeries occur annually in the European Union, representing a significant market opportunity for the EnCompass Clamp.
AtriCure, Inc. (Nasdaq: ATRC) has announced the successful treatment of the first patient with its newly 510(k) cleared AtriClip® FLEX-Mini™ device. This innovative product is now the smallest profile surgical LAA device available in the market, building upon AtriCure's proven AtriClip platform. The FLEX-Mini offers enhanced access and increased visibility for physicians, featuring a fully enclosed design with parallel beams for continuous closing force.
Key features of the AtriClip FLEX-Mini include:
- Low-profile design for improved visibility
- Ergonomic handle for single-handed placement
- Optimal pressure on atrial tissue
AtriCure, Inc. (Nasdaq: ATRC) has received an expanded CE-Mark indication for its AtriClip® devices in Europe. The devices are now indicated for use in patients at high risk of thromboembolism for whom left atrial appendage (LAA) exclusion is warranted. This expansion is based on substantial clinical evidence demonstrating a reduction in stroke events for patients receiving an AtriClip device.
The AtriClip family of devices are designed to exclude, electrically isolate, and eliminate the LAA during cardiac surgery. With over 550,000 patients treated worldwide, AtriCure has observed significant impact on patient care. The expanded indication confirms clinical evidence that strokes can be reduced in high-risk patients. Over 85 peer-reviewed studies involving more than 11,000 patients have been published on the safety and efficacy of AtriClip devices since 2007.
AtriCure, Inc. (Nasdaq: ATRC) reported strong Q2 2024 financial results, with worldwide revenue reaching $116.3 million, a 15.2% increase year-over-year. The company generated positive cash flow of $8.1 million in Q2. U.S. revenue grew by 12.5% to $95.5 million, while international revenue surged by 29.4% to $20.7 million. Despite revenue growth, AtriCure reported a loss from operations of $7.2 million and a net loss per share of $0.17. The company updated its full-year 2024 revenue guidance to $456-$461 million, reflecting approximately 15% growth at the midpoint. AtriCure expects full-year 2024 Adjusted EBITDA of $26-$29 million and an adjusted loss per share of $0.74-$0.82.
AtriCure (Nasdaq: ATRC), a leader in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has announced its participation in the Canaccord Genuity 44th Annual Global Growth Conference. The company's management is set to present on Tuesday, August 13, 2024, at 10:30 am EST.
Investors and interested parties can access a live audio webcast of the presentation through the 'Investors' section of AtriCure's website at https://ir.atricure.com. This event provides an opportunity for AtriCure to showcase its innovations and growth strategies to a global audience of investors and industry professionals.
AtriCure, Inc. (Nasdaq: ATRC) has received regulatory approval from China's National Medical Products Administration (NMPA) to market and sell several models of its AtriClip® Left Atrial Appendage (LAA) Exclusion System. This innovative device is designed to exclude and electrically isolate the LAA during cardiac surgery, addressing a major source of blood clots in patients with atrial fibrillation (Afib).
The approval marks a significant milestone in AtriCure's global expansion strategy, opening up a substantial market opportunity in China. The company plans to partner with leading medical institutions and professionals in China to provide comprehensive training and support. AtriClip devices have been successfully used in over 550,000 patients worldwide, demonstrating robust clinical data on safety and efficacy.
AtriCure (Nasdaq: ATRC) will announce its second quarter 2024 financial results on July 30, 2024. The company specializes in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management. A webcast will be hosted at 4:30 p.m. Eastern Time on the same day to discuss the results. Interested individuals can register online, and both live and replay versions of the webcast will be accessible at AtriCure's investor relations site.
AtriCure, a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, announced its participation in the 2024 Leerink Partners Healthcare Crossroads Conference.
A fireside chat with AtriCure’s management is scheduled for Wednesday, May 29, 2024, at 10:40 a.m. Central Time. The live audio webcast will be accessible via the 'Investors' section of the company’s website.
AtriCure, Inc. reported first-quarter 2024 financial results, with worldwide revenue of $108.9 million, a 16.4% increase year over year. The U.S. revenue was $90.2 million, up 15.4% from first quarter 2023. International revenue increased by 21.5% to $18.6 million. Gross profit was $81.3 million with a gross margin of 74.7%. Loss from operations was $10.9 million. Adjusted EBITDA was $2.8 million. Full-year 2024 revenue is projected to be $459 million to $466 million, with adjusted EBITDA expected to be $26 million to $29 million.
AtriCure, Inc. (ATRC) will be participating in the 2024 Bank of America Securities Healthcare Conference. The company is known for its innovative surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management. The management will present on May 14, 2024, at 10:15 a.m. PDT.
FAQ
What is the current stock price of Atricure (ATRC)?
What is the market cap of Atricure (ATRC)?
What does AtriCure, Inc. specialize in?
What is the Isolator® Synergy™ Ablation System?
What is AtriClip?
How does AtriCure distribute its products?
What types of products does AtriCure offer?
Where does AtriCure generate most of its revenue?
Are AtriCure’s products used internationally?
What makes AtriCure's products unique?
Where can I find more information about AtriCure?
What are AtriCure’s latest achievements?
